Abstract. Alveolar echinococcosis (AE) is a prevalent epidemic in the northern hemisphere, especially in central Europe and western China. Serum diagnosis is important for patients with AE, especially during the first screening. The present study purified the recombinant Em18-GST (rEm18-GST), and detected its diagnostic performance in human alveolar echinococcosis patients of Xinjiang, China with immunoblotting (IB) and enzyme-linked immunosorbent assay (ELISA). Serum samples were collected from 50 patients with AE, 222 patients with cystic echinococcosis (CE), 158 patients with other unrelated infections and 106 healthy individuals. The IB results showed that serum samples of 47 patients with AE and 12 patients with CE were rEm18-positive. However, only one sample from patients with cancer showed a cross-reaction with rEm18 in IB. The overall sensitivity was 94%, and the total specificity was 96.58%. For the rEm18 results using ELISA, the sera of 46 patients with AE were positive, and the overall sensitivity was 92%. In conclusion, compared with imaging tools, including computed tomography, magnetic resonance imaging and positron emission tomography, rEm18 has considerable advantages for AE serodiagnosis.
Introduction
Alveolar echinococcosis (AE) is a lethal hepatic disease caused by the Echinococcus multilocularis (E. multilocularis) infection at the larval stage. Humans may get infected by swallowing the contaminated eggs. The disease is a prevalent epidemic in the northern hemisphere, especially in central Europe and western China (1, 2) . The larval vesicles of the parasite propagate asexually in liver, the same as the tumor. Generally, the clinical symptoms could persist for a long time (up to 10 years), which usually causes liver dysfunction. At present, most AE patients are diagnosed with imaging methods, including radiology, magnetic resonance imaging, ultrasonography, and computed axial tomography (3) (4) (5) (6) . However, performing these methods in remote areas is relatively hard where the resources are limited. Thus, it is of great significance to diagnose AE patients in remote areas. Immunodiagnostic has been suggested as a possible method for screening a large population and as being suitable for diagnosis of AE (7, 8) .
To identify and screen human AE, a 2-step procedure for diagnosis has been recommended by the World Health Organization (WHO) (9) . First, Serologic screening is firstly conducted. The commonly used techniques included enzyme-linked immune sorbent assays (ELISAs), radio allegro sorbent tests (RAST), and indirect hemagglutination (IHA). Then, the results are further confirmed by the immunoelectrophoresis (IEP) or immunoblot (IB). Recently, Em18 has been isolated from the metacestode of the parasites (10) , and was demonstrated to have high sensitivity and specificity for AE diagnosis through ELISA or IB (8, 11, 12) . However, these studies only included a relatively small panel of AE serum samples (approximately 20-30 AE patients). The value of recombinant Em18 (recEm18) in AE diagnosis with a large number of serum samples is not reported yet.
Here in this study, we have cloned and expressed the rEm18 in Escherichia coli (E. coli) as a GST fusion protein. A large number of serum samples were collected from patients in Xinjiang. Our aim was to clarify whether recEm18 is of high sensitivity and specificity in the serodiagnosis of AE, both by using IB and ELISA. . The primer sequences were as follows: Up-stream primer, 5'-CCG GAA TTC ATG AAG GAG TCT GAC TTA GCG GAT-3' and downstream primer, 5'-CCG CTC GAG TTT GAG GTT GGC CAT CTT CGT-3'). The PCR conditions were 94˚C for 5 min followed by 35 cycles of 94˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 2 min. After that, the product was cloned into a pGEM-T plasmid vector (Promega Corporation) and sequenced.
Sequence analysis. Sequencing data were analyzed using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). The predicted Em18 protein sequences of E. multilocularis and other parasites were aligned using CLUSTAL (http://www.ebi. ac.uk/clustalw/#). The MEGA6.06 was used to construct the phylogenetic tree (13) and the neighbor-joining method (14) with 1,000 bootstrap replications was used.
Subcloning, expression, and purification of recombinant Em18 (rEm18).
The pET-41a (+)-Em18 plasmid was constructed by excising Em-18 sequence from thepGEM-T-Em-18 plasmid and ligating into the EcoRI and XhoI site of the pET-41a (+) expression vector (Novagen, Inc., Madison, WI, USA).The recombinant pET-41a (+)-Em18 plasmid was transformed into E. coli BL21 (DE3) cells (Novagen, Inc.). The expression of rEm18-GST fusion protein was induced with 1.0 mM isopropyl -β-D-thiogalactopyranoside (IPTG) for 3 h at 37˚C. The protein was purified using GST binding resin under native conditions. At last, the purified protein was quantified by the Bradford assay. Bovine serum albumin was used as a standard sample.
Immunoblot analysis (IB).
The rEm18-GST fusion protein was separated by 12% SDS-PAGE gels and then transferred onto a nitrocellulose membrane. After that, the membrane was cut into strips, with approximately 0.3 µg of rEm18-GST on each strip. The strips were blocked with 5% skim milk. Then, human serum samples (diluted 1:100) was added and incubated for 1 h at 37˚C. After rinsing with PBST for 3 times, the secondary antibodies of goat anti-human IgG conjugate with HRP (Sigma; Merck KGaA, Darmstadt, Germany) were added and incubated for 2 h at room temperature. Finally, the strips were incubated with diaminobenzidine (DAB) for 15 min at room temperature for color development.
ELISA. ELISA were performed using plates coated with rEm18. Briefly, microtitration plates (Nalge Nunc International, Roskilde, Danmark) were coated with 100 µl of antigen solution (1 µg/ml) per well in carbonate/bicarbonate buffer (pH 9.6) at 4˚C overnight. After washing PBST for three times, the plate was incubated with 5% skim milk for 1 h at 37˚C. After washing again, 100 µl of serum sample (1:100 dilution) was added into each well and incubated at 37˚C for 1 h. Then, 100 µl of secondary antibody (peroxidase-conjugated rabbit anti-human immunoglobulin G (IgG) (Sigma; Merck KGaA) was added, and the mixture was incubated for 1 h at 37˚C. Finally, 100 µl of substrate was added to each well and incubated for 15 min at 37˚C. sequence. The pET-41a (+)-Em18 plasmid was constructed and the expression of rEm18-GST was induced with IPTG. After that, the fusion protein was purified through GST affinity beads, which was approximately 51 kDa (Fig. 1) . These results indicate that Em18 from Sichuan and Xinjiang have little difference in the amino acid sequence.
Phylogenetic comparison of Em18 and Eg18. The neighbor joining method was used to construct a phylogenetic tree. As shown in Fig. 2 , Em18 was closely related to Eg18, Eg10, EmII/3 as well as E. granulosus tegument protein, and Moesin/ezrin/radixin protein. However, the homology of this recombinant antigen with human and other parasitic moesin family proteins was the lowest. Thus, the phylogenetic data suggested that AE patients can be easily distinguished from patients contaminated infected with other parasites by rEm18.
Diagnostic performance of rEm18-GST by IB and ELISA.
ELISA (Fig. 3) and IB (Fig. 4) methods were used to evaluate the diagnostic value of the purified rEm18-GST fusion protein.
The serum samples were collected from AE patients. As shown in Table II , rEm18-GST showed positive reactions with 94% (47/50) of serum samples from AE patients, as revealed by IB testing, and the ratio was 92% (46/50) by ELISA. For patients who had unrelated diseases, a total of 3.42% of the serum samples (n=380) had positive reaction with rEm18-GST, among which, 5.41% (12/222) of serum samples from CE patients cross-reacted with the recEm18-GST. One sample from lung cancer patient who have not the particular history, also cross-reacted with rEm18-GST. However, no positive results were observed with serum from patients with neurocysticercosis (n=9), patients with diseases (n=149), or healthy individuals (n=106). The statistical significance were not observed between IB and ELISA groups (P>0.05).
Discussion
Alveolar echinococcosis (AE) causes high chronic morbidity and mortality in Central Asia, European countries, North/Latin America and northwest China (15) . One of the clinical features of tissue-invasive larval cestodiases is slow progression with minimal symptoms and signs, unless infected parasites provoke acute symptoms (16) . Early diagnosis of AE can significantly improve the both quality of disease diagnosis and treatment. The multiple serological studies have been carried out that serology can be used to detect early (asymptomatic) cases in populations living in endemic areas (6, 17, 18) .
Immunodiagnostic of AE is doubtlessly one of the most valuable diagnostic methods in the early detection of AE infection (19) . In most cases, these methods are cheap, relatively easy to use, and are necessary for large-scale screening in high-risk groups (20) . Here, the fusion protein rEm18-GST was constructed and purified. The role of rEm18-GST in the early diagnosis of AE was investigated by IB and ELISA. Em2 is isolated from the metacestode of E. multilocularis (21) . As a species-specific natural antigen, Em2 has been widely used for serodiagnostic studies (22) and has shown encouraging results in the immunodiagnostic of human AE (23) . However, the sensitivity of Em2 in ELISA, with range of 77 to 92%, is dependent on the patient's geographical origin. The works on other recombinant E. multilocular molecules have also been undertaken for the diagnostic purposes, and the results are encouraging. The Em2 plus ELISA, which is a combination of Em2 with a II/3-10recombinant protein, has increased the sensitivity to 97% (21) . However, the Em2 plus assay has also shown a cross-reaction to CE (in 25.8% of cases), which is higher than that for individual Em2 (5.6%) or II/3-10 (6.5%), respectively. To explain why these similar proteins have distinct immunogenicity in AE and CE patients, Sako et al (10) have speculated that E. multilocularis may contact invasively and intimately with host tissues. For this reason, in CE patients, B-cell responses to Em18 might be low.
Further studies are needed to analyze the relationship of the Figure 3 . Diagnostic performance of rEm18-GST by ELISA. The cutoff value was defined as the value that was three times of the OD value of the negative control. AE (n=50), CE (n=222), paragonimiasis (n=32), Clonorchiasis (n=20), Schistosomiasis (n=7), Cancer (n=8), Neurocysticercosis (n=9), Cyst (n=6), Otherdisease (n=76), Healthy person (n=106). B-cell epitopes and Em18. The serodiagnostic performance of rEm13 protein (sensitivity and specificity) has also been analyzed (24, 25) , however, only a small numbers of serum samples were tested. Our results here suggest that the diagnostic performance of rEm18-GST by both IB and ELISA may be better than other reported reagents, particularly when a large number of serum samples were tested.
To sum up, our results suggest that rEm18 diagnosis is both easy to use and cheap. This method may be used to confirm the clinical findings of AE and a follow-up to surgery or pharmacological therapy (26) . And, this method has the minimum requirement for equipment and time, especially during the first screening.
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